StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
7133.T$989.00+1.23%
Fair $989.00+0.0%

7133.T

HYUGA PRIMARY CARE Co.,Ltd.

Healthcare / Medical Care FacilitiesTokyo

$989.00

+12.00 (+1.23%)

Fairly Valued+0.0%Fair Value $989.00Fund rank 32/100 · Data gapFallback financials|
SA 45/C
F-Score: 8/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $392.7M · quality 62.0/100

Data gap 32/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 66/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

45/100

C

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 7133.TLocal privado en este navegador · HYUGA PRIMARY CARE Co.,Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$7.1B

P/E

14.5x

↓

EV/EBITDA

7.2x

↓

ROE

30.3%

↑

Gross Margin

24.1%

↓

Debt/Equity

1.12

↑
52-Week Range$989
$836$1593

TradingView lightweight chart

7133.T price, volumen y niveles de valoración

Último $989.00Periodo -54.4%
Fair value: $989.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+20.0%

FCF CAGR

+19.7%

FCF margin

3.9%

FCF / Net income

0.55x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $9.98B · net income $719.0M · FCF $392.7M

2022-FY → 2025-FY

Gross margin

24.1%+2.7% pts

Operating margin

10.5%+1.6% pts

Net margin

7.2%+1.5% pts

FCF margin

3.9%-0.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$9.98B$9.98B$8.29B$6.66B$5.78B
Net Income$719.0M$719.0M$441.0M$382.9M$328.5M
EBITDA$1.29B$1.29B$854.4M$627.3M$568.7M
EPS97.9297.9259.2650.8243.32
Gross Margin24.1%24.1%22.7%23.5%21.4%
Operating Margin10.5%10.5%8.6%8.0%9.0%
Net Margin7.2%7.2%5.3%5.8%5.7%
Balance Sheet
Debt/Equity1.121.121.700.170.31
Current Ratio1.481.48———
Cash Flow
Free Cash Flow$392.7M$392.7M$473.2M$102.6M$228.9M
Returns
ROE30.3%30.3%26.8%25.8%30.6%
Valuation
P/E14.4614.4631.7846.2885.87
EV/EBITDA7.237.2318.8727.7548.91
P/B3.063.068.5311.9526.30
Growth & Yield
Revenue Growth20.5%20.5%24.5%15.1%—
EPS Growth65.2%65.2%16.6%17.3%—
Dividend Yield4.1%4.1%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-3.6%

fácil

EPS terminal req.

$87.76

Spread vs growth

68.8%

5Y implied EPS CAGR

1.6%

fácil

EPS terminal req.

$106.19

Spread vs growth

63.6%

10Y implied EPS CAGR

5.7%

razonable

EPS terminal req.

$171.01

Spread vs growth

59.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -30.2%

Total return

-30.2%

Start / end P/E

25.4x → 10.1x

EPS bridge

59.26 → 97.92

Residual

-39.3%

EPS growth+65.2%
Multiple rerating-60.2%
Dividend+4.1%
Residual / FX / buybacks / cross-term-39.3%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.